BioSpace News Archive

Haemonetics Corporation announced its intention to offer, subject to market and other conditions, $425,000,000 aggregate principal amount of Convertible Senior Notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the fourth quarter and full year ended December 31, 2020, and recent operational highlights.

Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Chief Executive Officer, will present at both the 42 nd Annual Raymond James Institutional Investors Conference and the Barclays Global Healthcare Conference. The presentation at Raymond James on Wednesday, March 3, 2021 will begin at 9:10 a.m. Eastern time.

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and twelve-month periods ended December 31, 2020.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA’s Office of Health Technology 2 (Cardiovascular Devices) has communicated its intent to hold a Circulatory Systems Device

INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer.

Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering in which it intends to offer and sell $200.0 million of shares of its common stock.

FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2020 and provided an update on the company’s recent developments.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following virtual healthcare conferences